(Q34491459)

2 August 2017

1 reference

title

ECNP Consensus Meeting March 2000. Guidelines for investigating efficacy in GAD. (English)

1 reference

2 August 2017

D Montgomery

1

1 reference

2 August 2017

European College of Neuropsychopharmacology

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

European Neuropsychopharmacology

2 August 2017

published in

1 reference

2 August 2017

volume

12

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

81-87

1 reference

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

A comprehensive psychopathological rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Mental health economic studies from developing countries reviewed in the context of those from developed countries

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

The measurement of disability.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

Phenomenology and course of generalised anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900147-X

7 January 2021

10.1016/S0924-977X(01)00147-X

Identifiers

DOI

1 reference

2 August 2017

1 reference